- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02416765
Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes
An Open-label, Randomized, Five-way, Cross-over Study to Compare the Efficacy of Single- and Dual-hormone Closed-loop Operations Combined With Either Conventional Carbohydrate Counting or a Simplified Qualitative Meal-size Estimation, and Sensor-augmented Pump Therapy in Regulating Glucose Levels in Adults With Type 1 Diabetes
Postprandial meal glucose control with closed-loop systems (CLS) still needs some improvements. In the postprandial period, sensor delay in detecting blood glucose rise after a meal together with delays in insulin absorption expose patients to early risk of hyperglycemia and then to late-postprandial hypoglycemia. Glucagon infusion in dual-hormone CLS has the potential to improve post-meal control as compared to single-hormone CLS allowing a better glucose excursion related to a more aggressive insulin infusion while minimizing hypoglycemic risk. Several approaches have been tested for the determination of prandial boluses during closed-loop operation.
The objective of this study is to test in outpatient unrestricted settings whether, in the context of closed-loop strategy, conventional meal carbohydrate counting could be reduced to a simplified qualitative meal size estimation without a significant degradation in overall glycemic control in adult patients with type 1 diabetes.
The investigators hypothesize that in outpatient free-living conditions: 1) Dual-hormone CLS with partial boluses is equivalent to dual-hormone CLS with full boluses in terms of mean glucose; 2) Single-hormone CLS with partial boluses is equivalent to single-hormone CLS with full boluses in terms of mean glucose. Secondary hypothesis are: 3) Dual-hormone CLS with partial boluses will decrease time in hypoglycemia compared to single-hormone CLS with partial boluses; 4) Dual-hormone CLS with partial boluses is better than sensor-augmented pump therapy in terms of mean glucose; 5) Single-hormone CLS with partial boluses is better than sensor-augmented pump therapy in terms of mean glucose.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H2W1R7
- Institut de Recherches Cliniques de Montreal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females ≥ 18 years old.
- Clinical diagnosis of type 1 diabetes for at least one year.
- The subject will have been on insulin pump therapy for at least 3 months and currently using a fast actin insulin analog (Lispro, Aspart or Guilisine).
- Last (less than 3 months) HbA1c ≤ 10%.
- Currently using carbohydrate counting as the meal insulin dose strategy.
Exclusion Criteria:
- Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.
- Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
- Ongoing pregnancy.
- Severe hypoglycemic episode within 1 month of screening.
- Agents affecting gastric emptying (Motilium®, Prandase®, Victoza®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose for 3 months. Otherwise, these medications are acceptable and will be kept stable during the entire protocol.
- Oral steroids unless patients present a low stable dose (e.g. 10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef®). Inhale steroids at stable dose in the last month are acceptable.
- Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator (e.g. unstable psychiatric condition).
- Failure to comply with team's recommendations (e.g. not willing to change pump parameters, follow algorithm's suggestions, etc).
- Living or planned travel outside Montreal (> 1h of driving) area during closed-loop procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sensor-augmented pump therapy
Patients will use conventional pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels.
|
Interventions will be conducted in outpatient settings.
Subject's usual insulin will be used.
Meals will not be standardized.
Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol.
Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits.
Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
|
Active Comparator: Single-hormone CLS with full boluses
Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels.
Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal.
Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
|
Interventions will be conducted in outpatient settings.
Subject's usual insulin will be used.
Meals will not be standardized.
Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol.
Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits.
Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer.
The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
The computer generated recommendations are based on a predictive algorithm.
|
Active Comparator: Single-hormone CLS with partial boluses
Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels.
A pre-meal partial prandial bolus will be given 10 minutes before the meal.
The partial bolus will be based on the estimated meal size (snack-regular-large-very large).
Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
|
Interventions will be conducted in outpatient settings.
Subject's usual insulin will be used.
Meals will not be standardized.
Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol.
Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits.
Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer.
The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
The computer generated recommendations are based on a predictive algorithm.
|
Active Comparator: Dual-hormone CLS with full boluses
Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels.
Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal.
Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
|
Interventions will be conducted in outpatient settings.
Subject's usual insulin will be used.
Meals will not be standardized.
Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol.
Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits.
Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer.
The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
The computer generated recommendations are based on a predictive algorithm.
In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
|
Active Comparator: Dual-hormone CLS with partial boluses
Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels.
A pre-meal partial prandial bolus will be given 10 minutes before the meal.
The partial bolus will be based on the estimated meal size (snack-regular-large-very large).
Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
|
Interventions will be conducted in outpatient settings.
Subject's usual insulin will be used.
Meals will not be standardized.
Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol.
Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits.
Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer.
The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
The computer generated recommendations are based on a predictive algorithm.
In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean glucose levels as measured by the glucose sensor.
Time Frame: 15 hours
|
The following comparisons will be done: 1) Dual-hormone CLS with partial boluses vs. dual-hormone CLS with full boluses; 2) Single-hormone CLS with partial boluses vs. single-hormone CLS with full boluses.
|
15 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean glucose levels as measured by the glucose sensor
Time Frame: 15 hours
|
The following comparisons will be done: 1) Dual-hormone CLS with partial boluses vs. single-hormone CLS with partial boluses; 2) Dual-hormone CLS with partial boluses vs. sensor-augmented pump therapy; 3) Single-hormone CLS with partial boluses vs. sensor-augmented pump therapy.
|
15 hours
|
Percentage of time of sensor glucose concentrations between 4 and 8 mmol/L
Time Frame: 15 hours
|
15 hours
|
|
Percentage of time of sensor glucose concentrations between 4 and 10 mmol/L
Time Frame: 15 hours
|
15 hours
|
|
Percentage of time of sensor glucose concentrations above 10 mmol/L
Time Frame: 15 hours
|
15 hours
|
|
Percentage of time of sensor glucose concentrations above 14 mmol/L
Time Frame: 15 hours
|
15 hours
|
|
Percentage of time of glucose levels spent below 4 mmol/L
Time Frame: 15 hours
|
15 hours
|
|
Percentage of time of glucose levels spent below 3.1 mmol/L
Time Frame: 15 hours
|
15 hours
|
|
Area under the curve of glucose values below 4 mmol/L
Time Frame: 15 hours
|
15 hours
|
|
Area under the curve of glucose values below 3.1 mmol/L
Time Frame: 15 hours
|
15 hours
|
|
Number of patients with at least one hypoglycemic event below 3.1 mmol/L with or without symptoms
Time Frame: 15 hours
|
15 hours
|
|
Total number of hypoglycemic event below 3.1 mmol/L
Time Frame: 15 hours
|
15 hours
|
|
Total insulin delivery
Time Frame: 15 hours
|
15 hours
|
|
Total glucagon delivery
Time Frame: 15 hours
|
15 hours
|
|
Standard deviation of glucose levels
Time Frame: 15 hours
|
15 hours
|
|
Total carbohydrate intake
Time Frame: 15 hours
|
15 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLASS10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on 15-hour intervention
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)RecruitingSedentary Behavior | Sedentary TimeUnited States
-
University of ConnecticutCompletedObesity | Nutrition PoorUnited States
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Maastricht University Medical CenterCompletedHaemodynamic Stability | Uremic ToxinsNetherlands
-
McGill UniversityDiabetes CanadaCompletedDiabetes Mellitus, Type 1Canada
-
McGill UniversityJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus, Type 1Canada
-
Duke UniversityNational Institute of Nursing Research (NINR)CompletedPressure UlcerUnited States
-
Sun Yat-sen UniversityUnknownType 2 Diabetes | Flash Glucose Monitoring | ConscienceChina
-
Duke UniversityKimberly-Clark CorporationCompleted